
🚨 73.8% response rate in advanced TNBC: promising early data for pumitamig + nab-paclitaxel. thelancet.com/journals/lanon… Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial In this phase 1b/2 trial, first-line pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, plus nab-paclitaxel demonstrated encouraging activity in 42 patients with advanced or metastatic triple-negative #BreastCancer . ➡️ At 35.2 months’ median follow-up, the confirmed objective response rate was 73.8%, including one complete response. ➡️ Grade ≥3 toxicities included neutropenia, leukopenia, proteinuria, and febrile neutropenia. No treatment-related deaths occurred. ✅These findings support further evaluation in larger global trials.













